Doxycycline hyclate

Research use only, not for human use.

Doxycycline Hyclate is a synthetic tetracycline derivative with similar antimicrobial activity.

Doxycycline Hyclate is a synthetic tetracycline derivative with similar antimicrobial activity.(In Vitro):Doxycycline hyclate (0.01-10 μg/mL, 4 d) affects growth of glioma cells only under high concentrations.Doxycycline hyclate (0.01-10 μg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 μg/mL and higher in SVG cells.Doxycycline hyclate (100 ng/mL, 1 μg/mL; 24 h) reduces proliferation of human cell lines.Doxycycline hyclate (0-250 μM, 72 h) inhibits cell viability of breast cancer cells .(In Vivo):Doxycycline hyclate (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner.

Doxycycline hyclate (0.01-10 μg/mL, 4 d) affects growth of glioma cells only under high concentrations.Doxycycline hyclate (0.01-10 μg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 μg/mL and higher in SVG cells.Doxycycline hyclate (100 ng/mL, 1 μg/mL; 24 h) reduces proliferation of human cell lines.Doxycycline hyclate (0-250 μM, 72 h) inhibits cell viability of breast cancer cells .Cell Viability Assay Cell Line:LNT-229, G55, and U343 glioma cells Concentration:0.01, 0.1, 1 or 10 μg/mL Incubation Time:4 days Result:Affected growth of glioma cells only under high concentrations (10 μg/mL).Cell Viability Assay Cell Line:SVG cells Concentration:0.01, 0.1, 1 or 10 μg/mL Incubation Time:24 hoursResult:Decreaseed MT-CO1 protein content with concentrations of 1 μg/mL and higher.Cell Proliferation Assay Cell Line:MCF 12A, 293T cells Concentration:100 ng/mL, 1 μg/mL Incubation Time:96 hours Result:Caused reduced proliferation of MCF 12A and 293T cells at 1 μg/mL.Cell Viability Assay Cell Line:MCF-7, MDA-MB-468 cells Concentration:0-250 μM Incubation Time:72 hours Result:Inhibited breast cancer cells in a dose-dependent manner with IC50 values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively.

Doxycycline hyclate (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner. Animal Model:6-month-old female Heterozygous Col3a1-deficient (HT) mice Dosage:200 or 800 mg/kg Administration:Oral gavage; 200 or 800 mg/kg; once daily; 3 months Result:Reduced MMP-9 activity in a dose-dependent manner.

WC 2031

Microbiology/Virology

ribosome

16S ribosome| 30S ribosome

Infection

——

24390-14-5

512.9

C22H24N2O8·HCl·1/2C2H6O·1/2H2O

>98% (HPLC)

Water: 100 mg/mL (194.95 mM); DMSO: 100 mg/mL (194.95 mM)

CCO.C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O.O.Cl.Cl

(4S,4aR,5S,5aR,6R,12aR)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;ethanol;hydrate;dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years